<DOC>
	<DOCNO>NCT02321592</DOCNO>
	<brief_summary>The study design - demonstrate efficacy AFM13 optimize treatment schedule - decide whether AFM13 warrant investigation phase III clinical trial</brief_summary>
	<brief_title>GHSG-AFM13 An Open-label , Multicenter Phase II Trial With AFM13 Patients With Relapsed Refractory Hodgkin Lymphoma</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<criteria>Patients diagnosis classical HL reconfirm histopathology relapse refractory disease standard therapy include brentuximab vedotin Age : 18 year old ( gender ) ECOG performance status ≤2 Life expectancy &gt; 3 month Measurable site disease ≥ 1.5cm diameter evaluable CT/MRI FDGavid PET Completion , applicable , radiotherapy , chemotherapy , antibody immunoconjugates include brentuximab vedotin and/or another investigational drug could interact trial less 4 week ( 5 halflifes drug , whatever occurs later ) prior first dose study drug Completion , applicable , autologous stem cell transplantation ( ASCT ) least 3 month prior tofirst dose study drug Voluntary write informed consent performance studyrelated procedure part normal medical care , understand consent may withdraw subject time without prejudice future medical care Any significant disease ( HL ) clinically significant finding include psychiatric behavioral problem , medical history and/or physical examination finding would preclude subject participation study unstable angina pectoris , symptomatic congestive heart failure ( NYHA II , III , IV ) , myocardial infarction ≤ 6 month prior first study drug , uncontrolled cardiac arrhythmia , cerebrovascular accident ≤ 6 month study drug start severely impaired lung function define spirometry ( FEV1 ) DLCO ( diffuse capacity lung carbon monoxide ) 50 % normal predict value and/or O2 saturation 88 % less rest room air Liver disease indicate AST &gt; 3 ULN ( &gt; 5 ULN liver involvement present ) severe uncontrolled disease might increase risk associate study participation study drug administration impair ability evaluate patient patient complete study Major organ dysfunction ( except HLrelated reduce value e.g . case bone marrow organ infiltration ) indicate Absolute Neutrophil Count ( ANC ) ≤1.5 x 109/l Platelets &lt; 75 x 109/l Hemoglobin level ≤9.0 g/dl ( may maintain transfusion ) Total bilirubin &gt; 2 ULN ( &gt; 2 ULN direct bilirubin require ≤1.5 x ULN ) ; Alkaline Phosphatase &gt; 3 ULN , AST ALT ≥3 ULN ( unless due Hodgkin Lymphoma diagnose Gilbert´s Syndrome ) Blood creatinine level &gt; 2.0 mg/dl History previous malignancy ≤3 year prior first dose study drug except basal squamous cell carcinoma skin , cervical carcinoma situ completely resect melanoma stage TNMpT1 Patients history HIV seropositivity , chronic active hepatitis , another uncontrolled active infection within 4 week prior first dose study drug Patients evidence current central nervous system ( CNS ) involvement Prior allogeneic stem cell transplantation ( SCT ) Patients receive systemic corticosteroid treatment &gt; 10 mg daily prednisone equivalent chronic systemic immunosuppressive agent within 2 week prior first dose study drug study treatment Major surgery within 4 week prior first dose study drug Known hypersensitivity recombinant proteins excipient drug formulation General intolerance protocol medication include obligatory concomitant medication Pregnant nursing woman woman childbearing potential willing use effective form contraception participation study least 3 month thereafter . Male patient willing ensure study least 3 month thereafter father take place Patient´s lack accountability , inability appreciate nature , mean consequence trial formulate his/her wish correspondingly Patients unwilling comply protocol Patients relationship dependence employeremployee relationship sponsor investigator</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Hodgkin Lymphoma</keyword>
	<keyword>AFM13</keyword>
	<keyword>Natural Killer Cells</keyword>
</DOC>